EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in Therapy for the Neurodegenerative Disorder Ataxia-Telangiectasia

Sam Nayler, Simon Foster iD, Martin Lavin, David Coman iD

International Journal of Molecular Sciences · 17.08.2026 · 27 (16) · 7347

DOI: 10.3390/ijms27167347 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.08.2026. Verfasst von Sam Nayler und 3 weiteren Autor:innen. Beteiligte Einrichtung: QIMR Berghofer Research Institute, Brisbane, QLD 4006, Australia. Hauptthemen laut MEDLINE: Ataxia Telangiectasia, Genetic Therapy, Neurodegenerative Diseases. Die Arbeit nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BrAshA-T, Action for A-T, Medical Research Future Fund Australia, Bellberry Ltd-Viertel Foundation Senior Medical Research Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

At present, there is no cure for the human genetic disorder ataxia-telangiectasia (A-T), which is managed by supportive care. This disorder arises due to mutations in the ATM (ataxia-telangiectasia mutated) gene and is characterised by a defect in the response to DNA damage, oxidative stress, mitochondrial dysfunction and immune deficiency. The ATM protein is activated by DNA damage, reactive oxygen species (ROS), and a variety of other stimuli, which leads to the phosphorylation or altered cellular localisation of multiple protein substrates that participate in cellular defence pathways. ATM plays a central role in orchestrating cellular defence against stress, which forms a focal point for approaches to treating the symptoms in this disorder. These strategies involve boosting mitochondrial function and dampening the inflammatory response. A more direct approach to treatment is gene therapy, yet the leading method using Adeno-Associated Virus (AAV) is hampered by the large size of the ATM gene itself. The use of antisense oligonucleotides (ASO) as an alternative gene therapeutic approach to treat patients has been increasingly utilised. However, only certain mutations fit the criteria for ASO-based intervention, which encourages rescue through readthrough of premature truncation mutations. For this reason, small-molecule-based therapies addressing the multi-system nature of the disease are urgently required. We address these different approaches to therapy and the outcome of numerous recent clinical trials with A-T patients, as well as ongoing research that has potential to lead to therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia TelangiectasiaGenetic TherapyNeurodegenerative DiseasesHumansAtaxia Telangiectasia Mutated ProteinsAnimalsMutationOligonucleotides, AntisenseReactive Oxygen SpeciesDNA Damage

Stichwörter der Autor:innen

A-TASOATMDNA repairROSataxiacerebellummitochondriatelangiectasiatherapy

Substanzen

Ataxia Telangiectasia Mutated ProteinsATM protein, humanOligonucleotides, AntisenseReactive Oxygen Species

Autor:innen und Institutionen

  • QIMR Berghofer Research Institute, Brisbane, QLD 4006, Australia.
  • Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
  • School of Biomedical Sciences, University of Queensland, St Lucia, QLD 4072, Australia.
  • Frazer Institute, University of Queensland, Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia.
  • Department of Paediatrics, Wesley Medical Research, Auchenflower, Brisbane, QLD 4066, Australia.
  • Department of Metabolic Medicine, Queensland Children's Hospital, South Brisbane, QLD 4101, Australia.

ORCID-Profile: Simon Foster, David Coman

Förderung

  • BrAshA-T, Action for A-T
  • Medical Research Future Fund Australia
  • Bellberry Ltd-Viertel Foundation Senior Medical Research Fellowship
  • Wesley Research Institute

Zitieren

APA

Nayler, S., Foster, S., Lavin, M., & Coman, D. (2026). Recent Advances in Therapy for the Neurodegenerative Disorder Ataxia-Telangiectasia. International Journal of Molecular Sciences, 27(16), 7347. https://doi.org/10.3390/ijms27167347

Vancouver

Nayler S, Foster S, Lavin M, Coman D. Recent Advances in Therapy for the Neurodegenerative Disorder Ataxia-Telangiectasia. International Journal of Molecular Sciences. 2026;27(16):7347. doi:10.3390/ijms27167347

BibTeX
@article{Nayler2026,
  author = {Nayler, Sam and Foster, Simon and Lavin, Martin and Coman, David},
  title = {Recent Advances in Therapy for the Neurodegenerative Disorder Ataxia-Telangiectasia},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7347},
  doi = {10.3390/ijms27167347}
}
Kostenlos starten →